GlassScriptPhysician profile
Michael Adam Klein
NPI 1588317432
$2,844.97
in general payments reported to CMS, 2019-2025
31 companies · $504 in 2025
The $504 reported for 2025 was more than what 75% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $944 · 2023: $953 · 2024: $444 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $345.44 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $334.23 | 2024-2025 | Lifevest |
| Abbvie INC. | $249.32 | 2022-2024 | |
| Amgen INC. | $166.58 | 2022-2023 | Prolia, Evenity |
| Lilly USA, LLC | $148.67 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.10 | 2022-2024 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $136.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.70 | 2022-2025 | Jardiance, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $118.50 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $116.59 | 2023 | |
| Glaxosmithkline, LLC. | $101.00 | 2022-2024 | Trelegy Ellipta |
| Medtronic, INC. | $87.03 | 2025 | Linq II |
| Otsuka America Pharmaceutical, INC. | $85.74 | 2022-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $81.05 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.60 | 2022-2023 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $66.44 | 2022-2024 | |
| Astellas Pharma US INC | $58.96 | 2023 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $53.38 | 2022-2023 | Quviviq |
| Alnylam Pharmaceuticals INC. | $48.28 | 2025 | Onpattro |
| Corcept Therapeutics | $44.49 | 2022 | |
| Supernus Pharmaceuticals, INC. | $37.55 | 2023 | Qelbree |
| Dexcom, INC. | $32.27 | 2023 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $31.77 | 2022 | |
| Horizon Therapeutics Plc | $26.15 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.55 | 2025 | Opsynvi |
| Corium, LLC | $23.18 | 2022-2023 | Azstarys |
| Chiesi USA, INC. | $20.93 | 2024 | Cleviprex, Kengreal |
| Bridgebio Pharma, INC. | $19.50 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $18.45 | 2024 | |
| Merck Sharp & Dohme LLC | $17.09 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.